GeoVax Advances Vaccine Programs Amid Global Health Crises While Reporting Q3 Financial Results

GeoVax Labs, Inc. reported its third quarter 2025 financial results while highlighting substantial progress across its vaccine and immunotherapy programs addressing critical global health challenges. The clinical-stage biotechnology company is advancing multiple initiatives that could significantly impact pandemic preparedness, immunocompromised patient care, and cancer treatment.

The company accelerated development of its GEO-MVA vaccine program in response to the World Health Organization's reaffirmation of mpox as a global public health emergency. With Clade I outbreaks continuing across Africa, Europe, and the U.S., GeoVax's platform represents a U.S.-based, scalable solution amid constrained vaccine supply. The program received favorable scientific advice from the European Medicines Agency, supporting a streamlined regulatory pathway. A new research collaboration with the University of Queensland and UniQuest will evaluate needle-free delivery using Vaxxas' high-density microarray patch platform, targeting improved thermostability and dose-sparing performance critical for global vaccine equity.

In its COVID-19 vaccine program, GeoVax presented compelling data for GEO-CM04S1, its multi-antigen vaccine designed for immunocompromised populations. Recent presentations at the 6th ESCMID Conference on Vaccines in Lisbon and iwCLL 2025 Workshop in Krakow demonstrated robust T-cell and cross-variant antibody responses in chronic lymphocytic leukemia and hematologic cancer patients. The data showed immune activity exceeding that of standard mRNA vaccines, with the CLL trial meeting its immunogenicity primary endpoint and prompting discontinuation of the comparator mRNA arm. The company plans to incorporate the Omicron KP.2 Spike gene for enhanced variant coverage in 2026 trials.

The oncology program saw expansion of Gedeptin into new solid tumor indications. Following publication of KEYNOTE-689 Phase 3 results confirming perioperative checkpoint inhibition in head and neck cancer, GeoVax announced plans for a Phase 2 trial evaluating Gedeptin combined with pembrolizumab and fludarabine in first-line, resectable head and neck squamous cell carcinoma. Preclinical studies are also expanding into triple-negative breast and cutaneous cancers in collaboration with Emory University's Winship Cancer Institute.

Company leadership emphasized alignment with U.S. policy priorities, noting that GeoVax's U.S.-based MVA platform supports bipartisan calls for onshoring and pandemic preparedness investments. The company's continuous avian cell line manufacturing process aligns with legislative goals to modernize domestic biomanufacturing and reduce dependency on foreign vaccine suppliers. Engagements continue with ASPR, BARDA, CEPI, Africa CDC, WHO, and UNICEF, reinforcing the company's commitment to biodefense and equitable access.

Financially, GeoVax reported a net loss of $6,318,914 for the three-month period ended September 30, 2025, compared to $5,815,468 for the comparable period in 2024. The company reported no government contract revenue for the quarter, compared to $2,789,484 in the third quarter of 2024, following BARDA's termination of the Project NextGen contract in April 2025. Research and development expenses decreased to $5,043,504 from $7,402,884 in the prior year period, primarily due to discontinued costs associated with the terminated BARDA contract and lower clinical trial and manufacturing costs. Cash balances stood at $5,008,997 as of September 30, 2025. Further information is available in the company's Quarterly Report filed with the Securities and Exchange Commission and on their website at https://www.geovax.com.